Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Banco Bilbao Vizcaya Argentaria SA (BBVA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Banco Bilbao Vizcaya Argentaria SA — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Banco Bilbao Vizcaya Argentaria SA trades at $25.8 (market cap $141.88B). The key difference: Banco Bilbao Vizcaya Argentaria SA is far larger — about 3.6× Alnylam Pharmaceuticals, Inc.'s market cap, and Banco Bilbao Vizcaya Argentaria SA pays a 4.2% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | BBVA | |
|---|---|---|
Market Cap | $39.89B | $141.88B |
Sector | Health | Financials |
52-Week High | $491.22 | $26.14 |
52-Week Low | $278.09 | $14.73 |
Enterprise Value | $38.15B | — |
Dividend Yield | — | 4.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
BBVA trades at $25.69, up 1.3% with a bullish technical outlook supported by moving averages. The bank shows strong fundamentals with 26.51% net income margin and 18.67% ROE, though recent legal challenges from Spain's High Court regarding a spying case present headwinds. Earnings have mostly beaten expectations, with Q1 2026 EPS of $0.60 exceeding the $0.57 forecast.
The stock offers value with a P/E of 12.39 and receives strong analyst support (53.85% buy ratings), but investors should weigh regulatory risks and volatile cash flows against the positive earnings trajectory and technical momentum for medium-term growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Banco Bilbao Vizcaya Argentaria SA
Despite its Spanish origins, BBVA generates three quarters of its profits in emerging markets, especially Mexico that contributes nearly half of BBVA's net profit. BBVA is overwhelmingly a retail and commercial bank with corporate and investment banking forming a smaller part of the overall business.
Read more on BBVA →
